A
Anthony Ingall
Researcher at Loughborough University
Publications - 29
Citations - 1284
Anthony Ingall is an academic researcher from Loughborough University. The author has contributed to research in topics: Alkyl & Ring (chemistry). The author has an hindex of 15, co-authored 29 publications receiving 1234 citations. Previous affiliations of Anthony Ingall include Fisons & AstraZeneca.
Papers
More filters
Journal ArticleDOI
Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy.
Anthony Ingall,John Dixon,Andrew Bailey,Mandy E. Coombs,David Cox,Judith I. McInally,Simon F. Hunt,Nicholas Kindon,Barry Teobald,Paul Willis,R.G. Humphries,P. Leff,Jane A. Clegg,James A. Smith,Wendy Tomlinson +14 more
TL;DR: The platelet P2T receptor plays a major role in platelet aggregation, and its antagonists are predicted to have significant therapeutic potential as antithrombotic agents.
Journal ArticleDOI
From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
Brian Springthorpe,Andrew Bailey,Patrick Barton,Timothy Nicholas Birkinshaw,Roger Bonnert,Brown Roger Charles,Chapman David,John Dixon,Simon Guile,R.G. Humphries,Simon F. Hunt,Francis Ince,Anthony Ingall,Kirk Ian,Paul D. Leeson,P. Leff,Richard J. Lewis,Barrie Martin,Dermot F. McGinnity,Michael Mortimore,Stuart W. Paine,Garry Pairaudeau,Anil Patel,Aaron Rigby,Robert J. Riley,Barry Teobald,Wendy Tomlinson,Peter J. H. Webborn,Paul Willis +28 more
TL;DR: The identification of a novel series of P2Y(12) receptor antagonists and exploitation of their SAR is described and the leading compound, 17 (AZD6140), is currently in a large phase III clinical trial for the treatment of acute coronary syndromes and prevention of thromboembolic clinical sequelae.
Journal ArticleDOI
Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase.
B.E. Crack,C.E. Pollard,M.W. Beukers,S.M. Roberts,Simon F. Hunt,Anthony Ingall,K.C.W. McKechnie,Adriaan P. IJzerman,P. Leff +8 more
TL;DR: The degree of potentiation of ATP and UTP effects elicited by FPL 67156 confirms previous results concerning the influence that ecto‐ATPase has on the position of E/[A] curves for metabolically unstable agonists.
Journal ArticleDOI
FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors.
TL;DR: FPL 66096 represents a novel pharmacological tool in the classification of P2‐purinoceptors and in the elucidation of the mechanisms involved in activation of platelets by ADP.
Journal ArticleDOI
New antiallergic pyrano [3,2-g]quinoline-2,8-dicarboxylic acids with potential for the topical treatment of asthma.
TL;DR: A number of antiallergic pyranquinolinedicarboxylic acid derivatives with potential for the topical treatment of asthma have been synthesized and are at present undergoing therapeutic evaluation.